350 related articles for article (PubMed ID: 29509538)
1. Distant Oncologic Outcome of Patients with Locally Advanced Unresectable and Metastatic Esophageal Cancer after Multimodality Treatment.
Anghel R; Constantinoiu S; Bacinschi X; Gales L; Toma RV; Trifanescu O
Chirurgia (Bucur); 2018; 113(1):116-122. PubMed ID: 29509538
[No Abstract] [Full Text] [Related]
2. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
3. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
[TBL] [Abstract][Full Text] [Related]
4. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
[TBL] [Abstract][Full Text] [Related]
6. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
7. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
8. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
9. Incidence of brain metastasis from esophageal cancer.
Welch G; Ross HJ; Patel NP; Jaroszewski DE; Fleischer DE; Rule WG; Paripati HR; Ramirez FC; Ashman JB
Dis Esophagus; 2017 Sep; 30(9):1-6. PubMed ID: 28859365
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis.
Hong JC; Murphy JD; Wang SJ; Koong AC; Chang DT
Ann Surg Oncol; 2013 Nov; 20(12):3999-4007. PubMed ID: 23800897
[TBL] [Abstract][Full Text] [Related]
11. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
[TBL] [Abstract][Full Text] [Related]
12. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal junction adenocarcinoma.
Swisher SG; Pisters PW; Komaki R; Lahoti S; Ajani JA
Curr Treat Options Oncol; 2000 Dec; 1(5):387-98. PubMed ID: 12057146
[TBL] [Abstract][Full Text] [Related]
14. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
15. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
18. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
19. [Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
[TBL] [Abstract][Full Text] [Related]
20. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92.
Becerra CR; Hanna N; McCollum AD; Becharm N; Timmerman RD; DiMaio M; Kesler KA; Yu M; Yan T; Choy H
J Thorac Oncol; 2013 Nov; 8(11):1425-9. PubMed ID: 24084441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]